Literature DB >> 24577341

[Chronic obstructive pulmonary disease (COPD). Current concepts and new therapeutic options].

A Klemmer1, T Greulich, A R Koczulla, C F Vogelmeier.   

Abstract

Chronic obstructive pulmonary disease (COPD) is a very common chronic disease with increasing prevalence. Inhaled particles and gases (in particular tobacco smoke) induce chronic inflammation of the airways accompanied by a not fully reversible airflow limitation. Destruction of lung tissue and deterioration of gas exchange may follow. In parallel, several comorbidities can be observed. The COPD assessment was revised and now takes into account lung function, the patients' symptoms, and history of exacerbations. More recently, several new long-acting bronchodilators received approval. Combination products, consisting of long-acting β2-agonists and long-acting anticholinergics, and a new combination of a long-acting β-agonist and an inhaled corticosteroid will follow in the near future. Smoking cessation is of central importance.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24577341     DOI: 10.1007/s00108-013-3406-5

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  44 in total

Review 1.  Influenza vaccine for patients with chronic obstructive pulmonary disease.

Authors:  P J Poole; E Chacko; R W B Wood-Baker; C J Cates
Journal:  Cochrane Database Syst Rev       Date:  2006-01-25

Review 2.  [Pneumococcal vaccine: protection of adults and reduction of antibiotic resistence by vaccination of children with a conjugated vaccine].

Authors:  Mathias W Pletz
Journal:  Med Monatsschr Pharm       Date:  2011-06

3.  Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.

Authors:  Paul W Jones; Dave Singh; Eric D Bateman; Alvar Agusti; Rosa Lamarca; Gonzalo de Miquel; Rosa Segarra; Cynthia Caracta; Esther Garcia Gil
Journal:  Eur Respir J       Date:  2012-03-22       Impact factor: 16.671

Review 4.  Pulmonary rehabilitation for chronic obstructive pulmonary disease.

Authors:  Y Lacasse; R Goldstein; T J Lasserson; S Martin
Journal:  Cochrane Database Syst Rev       Date:  2006-10-18

Review 5.  Mucolytic agents for chronic bronchitis or chronic obstructive pulmonary disease.

Authors:  Phillippa Poole; Peter N Black; Christopher J Cates
Journal:  Cochrane Database Syst Rev       Date:  2012-08-15

6.  Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease.

Authors:  W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson
Journal:  Eur Respir J       Date:  2003-01       Impact factor: 16.671

7.  Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF).

Authors:  Robert J Mentz; Daniel Wojdyla; Mona Fiuzat; Karen Chiswell; Gregg C Fonarow; Christopher M O'Connor
Journal:  Am J Cardiol       Date:  2012-11-29       Impact factor: 2.778

8.  Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.

Authors:  Mark T Dransfield; Jean Bourbeau; Paul W Jones; Nicola A Hanania; Donald A Mahler; Jørgen Vestbo; Andrew Wachtel; Fernando J Martinez; Frank Barnhart; Lisa Sanford; Sally Lettis; Courtney Crim; Peter M A Calverley
Journal:  Lancet Respir Med       Date:  2013-04-12       Impact factor: 30.700

9.  Health status and the spiral of decline.

Authors:  Paul W Jones
Journal:  COPD       Date:  2009-02       Impact factor: 2.409

Review 10.  Combined corticosteroid and long-acting beta-agonist in one inhaler versus placebo for chronic obstructive pulmonary disease.

Authors:  L Nannini; C J Cates; T J Lasserson; P Poole
Journal:  Cochrane Database Syst Rev       Date:  2007-10-17
View more
  1 in total

Review 1.  [Somatic morbidity in the mentally ill].

Authors:  W Hewer; F Schneider
Journal:  Nervenarzt       Date:  2016-07       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.